Under the terms of the agreement, Voyager will receive an upfront payment of $15 million and could potentially earn up to $305 million in milestone payments and royalties associated with the development, regulatory, and commercial progress of the licensed capsid.
Alfred W. Sandrock, Jr., M.D., Ph.D., CEO of Voyager Therapeutics, highlighted the significance of the partnership, stating, “Novartis is a global leader in gene therapy, and we view their continued selection of our IV-delivered, blood-brain barrier-penetrant capsids as strong validation of our TRACER capsid discovery platform.” The partnership between Voyager and Novartis now encompasses five gene therapy programs, including targets for Huntington’s disease, spinal muscular atrophy, and three other undisclosed indications.
TRACER™ Capsid Discovery Platform
Voyager’s TRACER™ platform is designed to facilitate the discovery of novel adeno-associated virus (AAV) capsids using an RNA-based screening approach. This platform has shown promise in preclinical studies, where intravenous delivery of TRACER-generated capsids demonstrated broad transduction across central nervous system regions and cell types. The TRACER platform’s capability to cross the blood-brain barrier effectively positions Voyager’s capsids for various gene therapy applications targeting neurological diseases.
About Voyager Therapeutics
Voyager Therapeutics, Inc. is committed to leveraging human genetics to develop treatments and potential cures for neurological diseases. The company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Parkinson’s disease, among others. Voyager’s innovative TRACER™ platform has enabled the development of novel capsids designed for high brain penetration, enhancing the delivery of genetic medicines via intravenous administration.
Voyager collaborates with prominent industry partners such as Alexion, AstraZeneca Rare Disease, Novartis, Neurocrine Biosciences, and Sangamo Therapeutics to advance its gene therapy programs.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Nanoscope Therapeutics Publishes Breakthrough Clinical Data Demonstrating Significant Vision Restoration in Retinitis Pigmentosa with Novel AAV-based MCO-010 Gene Therapy
Nanoscope Therapeutics has announced the publication of highly encouraging Phase 1/2a clinical trial data in the esteemed journal Molecular Therapy, showcasing significant vision restoration in patients suffering from retinitis pigmentosa (RP), a debilitating...
Capsida’s AAV CAP-004 Gene Therapy Shows Promise for Friedreich’s Ataxia in Primate Study at MDA Conference
Capsida Biotherapeutics' experimental gene therapy, CAP-004, for Friedreich's ataxia (FA), has demonstrated promising preclinical results in nonhuman primates. Research presented by Capsida at the 2025 MDA Clinical & Scientific Conference showed that a single...
FDA Grants Fast Track to Sanofi’s Chlamydia mRNA Vaccine
Sanofi is making significant strides in the fight against chlamydia, the most common sexually transmitted bacterial infection, for which there are currently no approved preventative vaccines. The French pharmaceutical group has recently been granted a fast-track...
Epicrispr Biotechnologies Announces $68M Series B to Advance First-in-Class FSHD Epigenetic Therapy to Clinic
Epicrispr Biotechnologies today announced the first close of its Series B financing, securing $68 million to support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
